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Protein ISGylation is unique among ubiquitin-like conjugation systems in that the expression and conju-
gation processes are induced by specific stimuli, mainly via the alpha/beta interferon signaling pathway. It has
been suggested that protein ISGylation plays a special role in the immune response, because of its interferon-
signal dependency and its appearance only in higher eukaryotic organisms. Here, we report the identification
of an ISG15-conjugating enzyme, Ubc8. Like other components of the protein ISGylation system (ISG15,
UBE1L, and UBP43), Ubc8 is an interferon-inducible protein. Ubc8 clearly mediates protein ISGylation in
transfection assays. The reduction of Ubc8 expression by small interfering RNA causes a decrease in protein
ISGylation in HeLa cells upon interferon treatment. Neither UbcH7/UbcM4, the closest homologue of Ubc8
among known ubiquitin E2s, nor the small ubiquitin-like modifier E2 Ubc9 supports protein ISGylation. These
findings strongly suggest that Ubc8 is a major ISG15-conjugating enzyme responsible for protein ISGylation
upon interferon stimulation. Furthermore, we established an assay system to detect ISGylated target proteins
by cotransfection of ISG15, UBE1L, and Ubc8 together with a target protein to be analyzed. This method
provides an easy and effective way to identify new targets for the ISGylation system and will facilitate related
studies.
ISG15 is an interferon (IFN)-inducible ubiquitin-like pro-
tein (ubl), and its expression and conjugation to target proteins
are highly induced upon viral or bacterial infection (20).
Among several hundred proteins induced by alpha/beta inter-
ferons (IFN-/), ISG15 is one of the most predominant (8,
10). Upon IFN treatment, ISG15 is detected as a free protein
and conjugated to target proteins in cells (28). In other cases,
it is found as an extracellular free protein (21). The secreted
form of ISG15 has been thought to function as a cytokine (6,
7, 44). So far, the known data regarding the ISG15 system
indicate that protein ISG15 modification (ISGylation) occurs
in a manner analogous to ubiquitylation or other ubl modifi-
cations (14, 20, 40). In human and rodent cells, ISG15 is ex-
pressed as a precursor protein with a C-terminal extension
(45), which is processed prior to conjugation in order to expose
Gly-Gly residues for conjugation (28). It has been observed
that the expression of the isopeptidase for precursor process-
ing seems to be independent of IFN signaling, though the exact
nature of the protease has not been identified (41).
Recently, Yuan and Krug (55) identified UBE1L as an E1
enzyme for ISG15. UBE1L was originally cloned as a gene
encoding a protein homologous to the ubiquitin-activating en-
zyme UBE1 (22). Interestingly, influenza B viral infection
blocks protein ISGylation by inhibiting the activation step
through the interaction of the NS1B viral protein with ISG15
(55). This finding suggests that ISGylation might be involved in
setting up antiviral states in the cell. Additional evidence for
UBE1L as an ISG15 E1 has been demonstrated by the recon-
stitution of UBE1L in K562 cells, which resulted in protein
ISGylation upon IFN treatment (32). K562 cells not trans-
fected with UBE1L express free ISG15 only in the presence of
IFN (28). UBE1L is also hypothesized to be a protein involved
in cancer development. The UBE1L gene is located on chro-
mosome 3p21, whose deletion is associated with small cell lung
cancer (22). UBE1L expression is not detectable in 14 human
lung cancer cell lines (34), suggesting a possible role in lung
cancer development.
Another enzyme identified for the ISG15 system is a de-
ISGylating protease UBP43 (USP18) (31). Mouse UBP43 was
initially cloned during the analysis of genes differentially ex-
pressed in both wild-type and leukemia fusion protein AML1-
ETO knock-in mice (27). Porcine ubp43 was cloned in a dif-
ferential screen from lung macrophages of virus-infected swine
(57). Li et al. (26) and Kang et al. (18) cloned human ubp43 in
screenings for RNase L substrates and for genes induced by
IFN in melanoma cell lines, respectively. The primary amino
acid sequence indicates that UBP43 is a member of the UBP
family of ubiquitin-specific proteases (27, 47). UBP43 contains
conserved Cys and His domains that are common in all UBP
family members (3, 4) but shows enzymatic specificity for
ISG15 (31). This enzyme specifically removes ISG15 from its
conjugates but does not partake in the precursor processing,
since UBP43-deficient cells can generate ISGylated proteins
upon IFN treatment (32). The most intriguing phenotype of
UBP43-deficient cells is their enhanced and prolonged activa-
tion of the Jak/Stat signaling pathway upon IFN-/ treatment
(32). The significant up-regulation of the UBP43 gene by viral
infection (or double-stranded RNA), IFN, and lipopolysaccha-
ride and the IFN hypersensitivity of UBP43 knockout mice all
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suggest that UBP43 might be involved in a number of pro-
cesses, including the control of cell proliferation, inflamma-
tion, stress, and immune response.
Although ISG15 itself has been known for 25 years, the
biological role of the modification has not been well studied.
Limited numbers of ISGylation targets have been identified,
including PLC1, ERK1, Jak1, Stat1, and serpin 2A, yet the
biological consequence of the modification is still not well
understood (12, 30). For the conjugation and deconjugation of
ISG15, only two enzymes have been found so far. Here, we
report that an IFN-inducible ubiquitin E2, Ubc8 (UbcH8 and
UbcM8 for human and mouse, respectively) is responsible for
protein ISGylation both in transfection experiments and in
vivo. We were also able to set up a practical assay system to
identify ISGylated proteins by the cotransfection of His-ISG15,
UBE1L, and Ubc8 followed by the purification of conjugates
by using Ni-nitrilotriacetic acid (NTA)–agarose and the detec-
tion of target proteins by Western blotting. This assay system
provides a powerful and effective way to identify new targets
for ISGylation and to confirm ISGylated proteins identified by
other methods, thus facilitating the study of protein ISGyla-
tion.
MATERIALS AND METHODS
Plasmid construction and mutagenesis. All mouse cDNA constructs except
serpin 2A were generated by PCR from a cDNA library prepared from hepatitis
B virus-infected hepatocytes (a kind gift of M. Robek and S. Uprichard, The
Scripps Research Institute). The mouse ISG15 (mISG15) gene was subcloned
into the pCAGGS vector without any tag (pCAGGS-mISG15), with five repeats
of the hemagglutinin (HA) tag (pCAGGS-5HA-mISG15), or with a six-His tag
(pCAGGS-6His-mISG15). UbcM8 and UbcM4 were also PCR amplified and
subcloned into the pFlagCMV2 vector (Sigma, St. Louis, Mo.). UbcM4 is 100%
identical to UbcH7 in amino acid sequences. Serpin 2A cDNA was amplified
from lipopolysaccharide-treated macrophage RNA and subcloned into the
pFlagCMV2 vector. UbcH8 cDNA was amplified from human erythrocyte leu-
kemia RNA (from Eiki Kanbe, The Scripps Research Institute) and subcloned
into the pFlagCMV2 vector. All of the constructs prepared by PCR were con-
firmed by sequencing. UBE1L cDNA was provided by Charles Buys (22) and
subcloned into pCAGGS containing a 5-end HA tag sequence generating
pCAGGS-HA-UBE1L. PLC1 (from Demin Wang, Blood Research Institute,
The Blood Center of Southeastern Wisconsin) was subcloned into the pCAGGS
vector. Constructs of pFlagCMV2-UBE1 and pFlagCMV2-Ubc9 are from Chin
Ha Chung (Seoul National University, Seoul, Korea), and pCEP-Erk1 was from
Melanie Cobb (University of Texas Southwest Medical Center). Plasmid con-
struct expressing Myc-Ub was obtained from Ron R. Kopito (52).
Mutagenesis for the replacement of the active-site cysteine to alanine of both
UBE1L (UBE1LC598A) and UbcM8 (UbcM8C86A) was performed by using a
QuikChange XL site-directed mutagenesis kit (Stratagene, La Jolla, Calif.) ac-
cording to the manufacturer’s instructions. Mutated constructs were confirmed
by sequencing.
Yeast two-hybrid screening. The Matchmaker Library Construction & Screen-
ing kit (BD Biosciences Clontech, Palo Alto, Calif.) was used to generate and
screen an IFN--induced library. IFN--induced RNA was generated by stimu-
lating 129 SvEv bone marrow macrophages with 100 U of IFN-/ml. RNA was
harvested at 6, 12, 18, and 24 h posttreatment and pooled, and poly(A) RNA
was isolated with a Poly A Spin mRNA isolation kit (New England BioLabs,
Beverly, Mass.). First-strand cDNA was synthesized by using random priming of
1 g of poly(A) RNA. To screen by mating, the IFN--induced library was
transformed with pGADT7-Rec into AH109 and the transformants were pooled
and aliquoted. The library was mated according to the manufacturer’s protocols,
with strain Y187 containing one of two forms of pGBKT7-ISG15 bait, full-length
ISG15 (amino acids 1 to 161) or the first domain of ISG15 (amino acids 1 to 79).
The mating mixture was plated on synthetic dropout (SD) plates lacking Ade,
His, Leu, and Trp. Colonies larger than 2 mm were restreaked on SD X-Gal
(5-bromo-4-chloro-3-indoyl--D-galactopyranoside) plates lacking Ade, His,
Leu, and Trp; clones that produced blue colonies and grew to 2 mm in diameter
were selected for sequencing. After sequencing, isolated clones were retrans-
formed into AH109 and mated with Y187 containing one of seven baits: pG-
BKT7 (empty vector), pGBKT7 expressing an irrelevant protein (p53 or lamin),
or pGBKT7 containing one of the four forms of ISG15 (full-length, ISG15-GG,
domain 1, or domain 2). Matings were initially plated on SD plates lacking Leu
and Trp to select for mated yeast and were then restreaked onto SD X-Gal plates
lacking Ade, His, Leu, and Trp.
Cell culture and transfections. HEK293T cells were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, Calif.) with 10% fetal bovine
serum (HyClone, Logan, Utah) and 2 mM L-glutamine (Invitrogen). Human
IFN- (Roferon-A) was from Roche Pharmaceuticals (Nutley, N.J.). Mouse
IFN- was from ICN Pharmaceuticals (Irvine, Calif.). For small-scale transfec-
tions, cells were grown on six-well plates and transfected by using PolyFect
reagent (QIAGEN, Hilden, Germany). For large-scale transfections, cells were
plated on 10-cm dishes and transfected by using calcium phosphate precipitation
as described previously (56).
Generation of fibroblasts from mouse lung. Primary lung fibroblasts were
generated from wild-type and STAT1 knockout mice (9) according to previously
published procedures (54). Briefly, lungs were aseptically excised from mice,
washed with phosphate-buffered saline (PBS), cut into small pieces, and digested
with trypsin (Invitrogen) for 30 min at 37°C. The resulting cell suspensions were
collected and resuspended in Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum and 2 mM L-glutamine. Cell suspensions were passed through
a cell strainer and cultured in the same medium. Seven days later, cells were
divided onto six-well plates. Twenty-four hours after replating, cells were treated
with 500 U of IFN-/ml for the indicated time periods.
siRNA for UbcH8. To construct MSCV-UbcH8 short hairpin RNA (shRNA),
hairpin structured UbcH8 small interfering RNA (siRNA) was amplified with U6
promoter by PCR with primers 5-TTTGGATCCCAAGGTCGGGCAGGAAG
AGGGCCTATTTCC-3 and 5-TTTGAATTCAAAAAGCCTTGCACCAAG
ACTTGCTCTCTTGAAGCAAGTCTTGGTGCAAGGCTTGGTGTTTCGTC
CTTTCCACAAGATATATAA-3 (1). The PCR product was digested with
BamHI and EcoRI and ligated to MSCV-PGKpuro (BD Biosciences Clontech)
digested with BglII and EcoRI. UbcH8 knockdown experiments were performed
by transiently expressing an shRNA construct for cells (29). To test the efficiency
of UbcH8 shRNA in cotransfection experiments, 293T cells were transfected
with MSCV-UbcH8 shRNA, pFlagCMV2-UbcH8, pCAGGS-mISG15, and
pCAGGS-HA-hUBE1L. The expression of UbcH8 and protein ISGylation were
checked 48 h posttransfection. To test the effect of UbcH8 shRNA in IFN-
induced protein ISGylation in vivo, HeLa cells seeded in six-well plates were
transfected with the control MSCV vector or MSCV-UbcH8 shRNA. Twenty-
four hours posttransfection, cells were selected with 2 g of puromycin/ml for
24 h to reduce the background ISGylation signal from untransfected cells. Dead
cells were washed out with PBS, and attached cells were then treated with 5,000
U of IFN-/ml for 24 h.
Immunoprecipitation and Ni-NTA–agarose pull-down assay. Cell extract (500
g) was subjected to either immunoprecipitation or Ni-NTA–agarose pull-down
assays. For immunoprecipitation, cells were lysed in modified radioimmunopre-
cipitation assay buffer (50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% NP-40,
0.25% deoxycholate, 0.1% sodium dodecyl sulfate [SDS]). Immunocomplexes
were precipitated with a mixture of protein A-agarose and protein G-agarose
(Amersham Biosciences, Piscataway, N.J.). Immunoprecipitates were washed
three times with the same buffer and boiled in SDS-polyacrylamide gel electro-
phoresis (PAGE) loading buffer. For Ni-NTA–agarose pull-down, cells were
lysed in PBS containing 1% NP-40 and 20 mM imidazole. Precipitates were
washed three times with the same buffer and subjected to SDS-PAGE followed
by Western blotting.
Antibodies and Western blot analyses. Antibodies against Flag (Sigma), HA
(Covance, Denver, Pa.), Myc (Sigma), and PLC1 (BD Biosciences) were pur-
chased from the respective manufacturers. Mouse anti-human ISG15 monoclo-
nal antibody (clone 5.1) was kindly provided by Ernest C. Borden (The Cleveland
Clinic Foundation, Cleveland, Ohio). Rabbit anti-mouse ISG15 polyclonal anti-
bodies were generated by using full-length mouse ISG15 and were immunoaf-
finity purified by using immobilized antigen as described in detail previously (30).
Rabbit anti-UbcM8 antibodies were generated by Covance by using glutathione
S-transferase (GST)–UbcM8 and were affinity purified by using GST-UbcM8-
agarose. Residual anti-GST antibodies were removed by passage through GST-
agarose. Western blotting was performed as described previously (31).
Two-dimensional gel electrophoresis. Protein samples were prepared in urea
lysis buffer {9 M urea, 2.5 mM EDTA, 2.5 mM EGTA, 1% dithiothreitol, and 4%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS)} and
centrifuged at 50,000 rpm (Ti50 rotor; Beckman) for 90 min. Isoelectric focusing
was performed by using 11-cm immobilized pH gradient gel strips (pH 3 to 10,
nonlinear; Bio-Rad, Hercules, Calif.) with 200 g of protein. Immobilized pH
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gradient gel strips were focused by ramping up the voltage in two steps, 0 to 250
V for 45 min and 250 to 8,000 V for 2.5 h, and by running at 8,000 V for a total
of 20,000 Vh. After equilibration, the proteins on the gel strips were resolved on
8 to 16% polyacrylamide gradient SDS-PAGE. Proteins were transferred onto
nitrocellulose membrane, and ISGylated proteins were detected by immunoblot-
ting with anti-human ISG15 monoclonal antibody (clone 5.1).
RESULTS
Ubc8 expression is correlated with protein ISGylation
through the Jak/Stat signaling pathway upon IFN-/ treat-
ment. Based on the mechanism of protein ubiquitylation and
other ubl conjugation (SUMOylation and Neddylation) (17,
53), protein ISGylation is predicted to involve the activity of
E1, E2, and E3 enzymes. Currently, only the E1 enzyme,
UBE1L, has been reported (55). To understand and regulate
protein ISGylation, it is important to identify the E2 and E3
enzymes and to define their functions in a biological system.
Each domain of ISG15 shares 30% homology with ubiquitin
(20). Furthermore, UBE1L was originally identified as a mem-
ber of the ubiquitin E1 family (22) and ISG15 protease UBP43
belongs to the ubiquitin protease family (27). Thus, it is highly
possible that ISG15 E2 is a member of the ubiquitin E2 family.
More importantly, both the expression of ISG15 and protein
ISGylation are highly induced upon interferon stimulation.
Therefore, we hypothesized that ISG15 E2 is not only a mem-
ber of the ubiquitin-conjugating enzyme family but also an
interferon-stimulated gene product. Based on published re-
ports and the information available from websites, we identi-
fied one candidate protein, UbcM8, a mouse homologue of
UbcH8, which fully matched the hypothesized criteria (37). We
use Ubc8 to denote either the human or the mouse enzyme,
unless otherwise specified. We also included 9-27 (Leu-13) and
1-8U proteins as candidates, because both of them are induced
by IFN and show similarities to ubiquitin E2s (25, 42).
The binding of IFN-/ to its receptors results in the acti-
vation of Jak tyrosine kinases, Jak1 and Tyk2, which are con-
stitutively associated with the receptors (38, 48). The Jaks, in
turn, phosphorylate specific tyrosine residues on the receptor,
allowing Stats to bind via SH2-phosphotyrosine interaction.
Jak kinases then phosphorylate Stat1 and Stat2. Phosphory-
lated Stat1 and Stat2, in addition to IRF9, form IFN-stimu-
lated gene factor 3 complex, translocate to the nuclei, and
activate gene expression via their interaction with the IFN-
stimulated response element (ISRE) in the promoters of IFN-
inducible genes (5). We tested whether the expression of
UbcM8 correlates with protein ISGylation upon IFN-/
treatment. As shown in Fig. 1A, UbcM8 expression and pro-
tein ISGylation are induced by IFN treatment and the two
events are temporally well correlated with each other. In
STAT-1-deficient fibroblasts, both protein ISGylation and
UbcM8 expression were inhibited upon IFN treatment while
the wild-type control showed UbcM8 expression and protein
ISGylation (Fig. 1B). Interestingly, we could detect basal-level
expression of UbcM8 and ISGylated proteins with wild-type
cells but not with STAT1-deficient fibroblasts (Fig. 1), suggest-
ing that the basal level of ISGylation and UbcM8 expression
are dependent on the Jak/Stat signaling pathway. Furthermore,
as shown in Fig. 1C, the promoter regions of genes related to
ISG15 modification, including ISG15, UBE1L, UBP43, and
UbcH8, contain the ISRE, which is responsible for the pro-
moter activation by IFN-/ (5, 11). Taken together, these
results show that ISGylation and UbcM8 expression are de-
pendent on the IFN signaling and are well coordinated, indi-
cating a possible involvement of UbcM8 in protein ISGylation
upon IFN signaling.
Yeast two-hybrid screening revealed the interaction between
ISG15 and Ubc8. In order to identify ISG15-interacting pro-
teins, we performed yeast two-hybrid screening with cDNA
libraries generated from IFN--induced RNAs, which were
constructed from 129 SvEv bone marrow macrophages stimu-
lated with 100 U of IFN-/ml. The library was screened by the
yeast mating method with two ISG15 baits, full-length ISG15
(amino acids 1 to 161) or the first ubl domain of ISG15 (amino
acids 1 to 79), as shown in Fig. 2A. For full-length ISG15 and
the first domain of ISG15, 1.2  106 and 4.6  105 colonies
were screened, respectively. From the initial screening, colo-
nies larger than 2 mm were restreaked on minimal selection
media containing X-Gal and clones that produced blue colo-
nies and grew to at least 2 mm in diameter were selected for
sequencing. A total of 107 clones were sequenced for the
full-length ISG15 screening, and 78 clones were sequenced for
the domain 1 screening. UbcM8 was identified once from the
domain 1 ISG15 screening and once from the full-length
ISG15 screening. The clone for UbcM8 from the domain 1
screening (amino acids 54 to 153) was used to test the inter-
action with lamin, p53, full-length ISG15, C-terminal LRGG-
exposed ISG15 (ISG15-GG, amino acids 1 to 155), or domain
FIG. 1. Correlation between Ubc8 expression and protein ISGyla-
tion. NIH 3T3 cells (A) and primary lung fibroblasts from wild-type
(WT) and STAT1/ mice (B) were treated with 500 U of mouse
IFN-/ml for the indicated times. Protein ISGylation and UbcM8
expression were detected by Western blotting. Molecular weight mark-
ers (in thousands) are indicated on the left side of each panel. Ponceau
staining shows the relative amounts of protein in the samples. (C) Pro-
moter regions of human genes for ISG15, UBE1L, UBP43, and UbcH8
contain ISRE (underlined). Conj., conjugate.
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1 or domain 2 of ISG15. As indicated in Fig. 2B, UbcM8
interacted with all forms of ISG15 tested, while it did not
interact with either lamin or p53. These results provided fur-
ther support that UbcM8 might act as a conjugating enzyme in
the protein ISGylation system.
Ubc8 mediates protein ISGylation together with UBE1L. In
order to test whether UbcM8 can support protein ISGylation
in cells, we performed transient transfection assays with
UbcM8, 9-27, and 1-8U. For the experiments shown in Fig. 3A,
mISG15, UBE1L, and two E2 candidates, UbcM8 and 9-27,
were transfected into 293T cells and protein ISGylation was
detected by Western blotting with an anti-mouse ISG15 anti-
body. UBE1L-transfected cells showed increased levels of
ISGylated proteins compared to cells transfected with ISG15
only (Fig. 3A, lanes 2 and 3). Most importantly, cells expressing
both UBE1L and UbcM8 showed a dramatic increase of pro-
tein ISGylation (Fig. 3A, lane 5), indicating that UbcM8 may
function as an ISG15 E2. On the other hand, 9-27 expression
did not support protein ISGylation (Fig. 3A, lane 4). We also
tested 1-8U protein in the same assay but did not detect any
increase in protein ISGylation (data not shown). Furthermore,
to confirm that the ISGylation signal shown in Fig. 3A was
specific for ISG15, we repeated the experiment with HA-
tagged ISG15 and anti-HA antibody to detect ISGylated pro-
teins. Again, the expression of UbcM8 together with UBE1L
markedly enhanced protein ISGylation in cells (Fig. 3B).
These results suggest that UbcM8 protein, but not 9-27 or
1-8U protein, functions as an E2 for protein ISGylation in our
experimental system.
Enzymatic activities of both UBE1L and UbcM8 are re-
quired for the conjugation of ISG15. To test if the protein
ISGylation in the above transfection experiments was directly
related to the enzymatic activity of UBE1L and UbcM8, we
mutated the cysteine residue located at the theoretical active
sites of the E1 (C598) and the E2 (C86), which are possibly
involved in thioester formation with ISG15 (13, 50), to alanine.
As shown in Fig. 4A, cells transfected with UBE1L-C598A or
UbcM8-C86A did not show protein ISGylation, indicating that
the cysteine is critical for the enzymatic activity of UBE1L and
UbcM8. Furthermore, UbcM8 expression in the absence of
UBE1L activity did not support protein ISGylation (Fig. 4A,
lane 3; Fig. 4B, lane 5). This result also illustrated that protein
ISGylation in the transfection assays results from the enzy-
matic function of both UBE1L and UbcM8.
The species homology for all of the components of the
protein ISGylation system, including Ubc8, is relatively low
compared to that of the members of other ubl systems. ISG15
itself is only 64% identical in amino acid sequences for human
and mouse, while other ubls (ubiquitin, small ubiquitin-like
modifier 1 [SUMO-1], and Nedd-8) are 100% identical.
UbcH8 and UbcM8 share 75% identity, but conjugating en-
zymes for other ubl systems show 95 to 100% identity. There-
fore, we questioned whether the proteins for the ISGylation
system are interchangeable between human and mouse. In
transfection assays, the expression of UbcH8 increased protein
ISGylation to the same extent as that of UbcM8 (Fig. 4B). This
finding shows that there is no species specificity for the ISGy-
lation reaction, despite the relatively low homology between
human and mouse E2 compared to other ubl systems.
Ubc8, but not its closest homologue UbcH7/UbcM4, can
support protein ISGylation. UbcH8 and its close homologue,
UbcH7 (55% identical with UbcH8 in amino acid sequences)
have been reported to interact with the same E3 ubiquitin
ligases, such as E6AP and HHARI (24, 35). We therefore
FIG. 2. Interaction between ISG15 and UbcM8 in yeast two-hybrid
screening. (A) Full-length ISG15 (amino acids 1 to 161) or the first ubl
domain of ISG15 (amino acids 1 to 79) was used as bait for yeast
two-hybrid screening to identify ISG15-interacting proteins. (B) The
clone from the domain 1 screening (UbcM8 amino acids 54 to 153) was
retransformed into AH109 and mated withY187 expressing lamin, p53,
full-length ISG15 (FL-ISG15), ISG15-GG, or domain 1 or domain 2 of
ISG15. The  and  indicate negative and positive interactions of
these proteins with UbcM8, respectively.
FIG. 3. Ubc8 mediates protein ISGylation. Plasmid constructs
pCAGGS-mISG15, pCAGGS-HA-hUBE1L, pcDNA3-HA-9-27, and
pFlagCMV2-UbcM8 (A), and pCAGGS-5HA-mISG15, pCAGGS-
HA-hUBE1L, and pFlagCMV2-UbcM8 (B) were transfected into
293T cells as indicated on the panels. Cells were harvested 48 h after
transfection, and protein extracts were analyzed on an SDS–8 to 18%
PAGE gel followed by Western blotting. Free or conjugated (Conj.)
forms of ISG15 were detected with rabbit anti()-mISG15 polyclonal
antibody (A) and with -HA antibody (B). Other protein expressions
were monitored with -HA or -Flag antibody. Plasmids are identified
by the ending letters and/or numbers of each designation. The asterisk
in panel B indicates nonspecific signal from -HA antibody.
VOL. 24, 2004 Ubc8 IS AN ISG15 E2 9595
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tested whether UbcH7/M4 or Ubc9, a well-characterized
SUMO-specific E2, could support protein ISGylation in con-
junction with UBE1L. We also checked whether UBE1 could
replace UBE1L in a protein ISGylation reaction with UbcM8.
The expression of UbcH7/M4 or Ubc9 with ISG15 and UBE1L
caused very minor, if any, increases in protein ISGylation com-
pared to the significant amounts of ISGylated proteins in
UbcM8-expressing cells (Fig. 5A), indicating that only Ubc8
functions for a protein ISGylation system. Moreover, UBE1
could not replace UBE1L for protein ISGylation in this assay
(Fig. 5A, lane 4). Similarly, we also tested whether the over-
expression of UBE1L could promote protein ubiquitylation in
the same transfection assays. 293T cells were transfected with
Myc-tagged ubiquitin and with increasing amounts of either
UBE1 or UBE1L. Expression of UBE1 increased ubiquity-
lated proteins in a dose-dependent manner, but UBE1L ex-
pression did not enhance protein ubiquitylation (Fig. 5B). Nei-
ther UbcM4 nor UbcM8 could increase the intensity of the
ubiquitylation signal in the assays (data not shown), probably
because the contribution of specific E2 to general ubiquityla-
tion is too minor to be detected in these assays. Taken to-
gether, the homologies of UbcH7/M4 and Ubc8 and of UBE1
and UBE1L are insufficient for functional redundancy (at least
for protein ISGylation), suggesting the existence of discrete
specificities among the ubl systems. This finding supports the
concept that interferon induction of the ISGylation system
represents a specific mechanism for altering cell physiology via
ISG15 functions independent of other ubls.
siRNA for UbcH8 blocks IFN-induced protein ISGylation.
After proving that Ubc8 could support protein ISGylation in
transfection assays, we next tested the hypothesis that Ubc8
depletion in vivo would cause decreased levels of ISGylated
proteins in IFN-treated cells. We designed an shRNA to spe-
cifically disrupt UbcH8 mRNA in an MSCV vector containing
a puromycin selection marker. First, we tested whether this
shRNA could decrease the expression of Flag-UbcH8 protein
as well as protein ISGylation in 293T cells. Plasmids for ISG15,
UBE1L, and UbcH8 were transfected into 293T cells with
increasing amounts of the MSCV-UbcH8 shRNA construct.
The expression of shRNA reduced the levels of Flag-UbcH8
protein by up to 70% and resulted in decreases in protein
ISGylation, while the amounts of ISG15 and UBE1L remained
unchanged (Fig. 6A). We then investigated the effect of
UbcH8 shRNA on IFN-induced protein ISGylation in HeLa
cells. As shown in Fig. 6B, shRNA expression reduced the
induction of IFN-induced UbcH8 mRNA by 70 to 80% in
comparison to the control. As a result, the amounts of ISGy-
lated proteins decreased significantly while the amount of free
ISG15 remained similar to that of the control (Fig. 6C). These
results strongly indicate that Ubc8 is a bona fide ISG15 E2,
responsible for increased ISGylation upon IFN treatment.
We also examined the effect of UbcH8 shRNA in more
detail to analyze whether the decreased expression of UbcH8
affects ISGylation of all target proteins equally or only blocks
ISGylation of specific substrates upon IFN treatment. Since we
cannot clearly distinguish individual ISGylated proteins in one-
dimensional gels, we used two-dimensional (2D) electrophore-
sis to separate and detect individual ISGylated proteins. HeLa
cells transfected with MSCV vector or MSCV-UbcH8 shRNA
FIG. 4. Mutational analysis of active-site cysteine on both UBE1L
and UbcM8. Plasmid constructs pCAGGS-mISG15, pCAGGS-HA-
hUBE1L, pCAGGS-HA-hUBE1LC598A, pFlagCMV2-UbcM8, and
pFlagCMV2-UbcM8C86A (A) and pCAGGS-mISG15, pCAGGS-
HA-hUBE1L, pFlagCMV2-UbcM8, and pFlagCMV2-UbcH8 (B) were
transfected into 293T cells in combinations as indicated. The expression of
proteins and protein ISGylation were analyzed as described for Fig. 3.
Plasmids are identified by the ending letters and numbers of each desig-
nation. Conj., conjugate.
FIG. 5. Ubc8 but not its closest homologue, UbcH7/UbcM4, can
support protein ISGylation. (A) Plasmid constructs pCAGGS-
mISG15, pCAGGS-HA-hUBE1L, pFlagCMV2-UBE1, pFlagCMV2-
UbcM8, pFlagCMV2-UbcM4, and pFlagCMV2-Ubc9 were trans-
fected into 293T cells. The expression of proteins and protein
ISGylation were analyzed as described for Fig. 3. (B) Increasing amounts
of Flag-UBE1 (pFlagCMV2-UBE1) or HA-UBE1L (pCAGGS-HA-
hUBE1L) were transfected into 293T cells together with Myc-Ub-express-
ing plasmid. After 40 h of transfection, cells were treated with 10 M
MG132 for 8 h. Protein ubiquitylation was analyzed by Western blotting
with anti-Myc antibody. Plasmids are identified by the ending letters and
numbers of each designation. Conj., conjugate.
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were prepared as described for Fig. 6C. The protein samples
were used for 2D gel electrophoresis, followed by immunoblot-
ting with ISG15 antibodies. As shown in Fig. 6D, we detected
individual ISGylated proteins. The decreased expression of
UbcH8 caused a general reduction of ISGylated proteins with-
out an obvious substrate preference. In summary, these results
indicate that Ubc8 is a major ISG15 E2 in HeLa cells for
general protein ISGylation upon IFN-/ signaling.
Detection of ISG15 conjugation to specific target proteins by
using an artificial conjugation system. One of the most critical
objectives in ubl protein modification systems is the establish-
ment of an easy assay system for detecting modification. We
took advantage of the identification of an E2 enzyme for
ISG15 to determine whether we could detect ISG15 conjuga-
tion of known target proteins (12, 30) by using a transfection-
based, artificial conjugation system. His-ISG15, UBE1L, and
UbcM8 were transfected into 293T cells together with either
PLC1, Flag-serpin 2A, or HA-Erk1. As shown in Fig. 7A, we
detected two major additional bands of PLC1 from the cell
extract in which PLC1 was transfected with the ISG15 con-
jugation system only. We were also able to see ISG15-modified
forms of serpin 2A or Erk1 from direct Western blots in the
same set of experiments, but only with long exposures of blots
(data not shown). Thus, we performed reciprocal pull-down
and immunoblot studies to detect clearly the ISG15 conjuga-
tion of these proteins. Cell extracts were immunoprecipitated
with anti-PLC1, anti-Flag (for serpin 2A), or anti-HA (for
Erk1) antibodies and blotted with anti-mISG15 antibody. Like-
wise, the same extracts were pulled down with Ni-NTA–aga-
rose for His-ISG15-conjugated proteins and blotted with anti-
PLC1, anti-Flag, or anti-HA antibodies. As shown in Fig. 7B
to D, we clearly detected ISG15-modified PLC1, serpin 2A,
and Erk1 only from the extracts transfected with ISG15 con-
jugation system only. To check the specificity of the conjuga-
tion system, we tested AML1B in the same transfection exper-
iments, followed by reciprocal pull-down and Western blot
analyses. No ISG15-conjugated AML1B was detected (Fig.
7E), indicating that ISG15 conjugation to targets in the trans-
fection system is a specific process.
DISCUSSION
IFNs are well-known cytokines that play pivotal roles in
antiviral, antibacterial, cell proliferation and differentiation,
and antitumor responses (46, 49). IFN-/ induces several
hundred genes through the Jak/Stat signaling pathway (8).
IFN-/ also triggers a dramatic increase of protein ISGylation
in most types of cells (20). However, neither the biological
effects of ISGylation nor enzymes involved in the conjugation
process have been well studied. In this paper, we identified a
new function of Ubc8, an IFN-inducible ubiquitin E2, as an
ISG15-conjugating enzyme. Interestingly, all of the proteins so
far identified for the ISGylation system, i.e., ISG15, UBE1L,
UBP43, and Ubc8, are induced by IFN (8, 10, 26, 37, 55),
suggesting their specialized functions in the innate immune
response. Based on the characteristics of UBE1L and UBP43,
we hypothesized that ISG15 E2 may be a member of the
ubiquitin-conjugating enzyme family and also an IFN-stimu-
lated protein. Ubc8 fits these criteria very well. Furthermore,
we also identified UbcM8 as an ISG15-interacting protein in
independent yeast two-hybrid screening (Fig. 2), which sup-
ported our original assumption. It is worth noting that domain
1 of ISG15, which is farther away from the ISG15 C-terminal
conjugating site, is sufficient for the interaction with Ubc8 in
this assay. In a cotransfection study, Ubc8 clearly mediated
protein ISGylation in the presence of UBE1L (Fig. 3), but the
inactive mutant form did not (Fig. 4B), indicating that Ubc8 is
a bona fide ISG15 E2. The variation of ISGylation in ISG15-
FIG. 6. siRNA for UbcH8 blocks IFN-induced protein ISGylation.
Increasing amounts of MSCV-UbcH8 shRNA construct were cotrans-
fected with pFlagCMV2-UbcH8, pCAGGS-mISG15, and pCAGGS-
HA-hUBE1L to 293T cells. Forty-eight hours after transfection, cell
extracts were subjected to Western blot analysis to examine protein
expression for Flag-UbcH8 and HA-UBE1L and also to examine pro-
tein ISGylation. Plasmids are identified by the ending letters and
numbers of each designation (A). HeLa cells were transfected with
control MSCV vector or MSCV-UbcH8 shRNA construct. Twenty-
four hours posttransfection, cells were selected with 2 g of puromy-
cin/ml for 24 h. Dead cells were washed out with PBS, and the remain-
ing HeLa cells were treated with 5,000 U of IFN-/ml. RNA and
protein samples were prepared after treating with IFN for 12 and 24 h,
respectively. RNA samples were analyzed by Northern blotting with an
UbcH8 probe (B), and proteins were subjected to Western blotting for
ISGylation (C). The asterisk in panel B indicates nonspecific signal.
For 2D gel electrophoresis, HeLa extracts were prepared as described
for panel C, separated on an 11-cm 2D gel until the 25-kDa marker
reached the bottom of the gel in order to get a better separation of
high-molecular-weight species, and subsequently probed with anti-
ISG15 antibody (D). Ponceau staining of the transferred membranes
showed equal loading of proteins (data not shown). Conj., conjugate.
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and UBE1L-transfected cells in each experiment most proba-
bly depends on transfection efficiencies. UBE1L is an enzyme
required for the initiation of ISGylation reaction. In that con-
text, we do not see a significant increase of ISGylation by
transfecting Ubc8 only. However, we always detect highly in-
creased amounts of ISGylated proteins in the presence of both
UBE1L and Ubc8, suggesting that the ISGylation reaction
requires both E1 and E2 enzymes. In our assay, we did not
detect ISGylated proteins in the presence of 9-27 or 1-8U
proteins (Fig. 3A and data not shown). These proteins have
been suggested as putative ISG15 E2s based on the limited
homology of the putative active-site cysteine region with Ubcs,
but no experimental evidence was provided (42). Both 9-27
and 1-8U are IFN-inducible genes and are located on a
genomic DNA fragment of less than 18 kb in humans (16, 25).
The 9-27 protein has been reported to be localized to the
surface of normal T cells (43), and the 1-8U protein also
contains a putative transmembrane region (42). Therefore, we
cannot rule out the possibility that these proteins still function
as ISG15 E2s under other conditions.
UBE1 and UbcH7/M4 or Ubc9 could not act as E1 and E2
to support protein ISGylation, suggesting that there is speci-
ficity among ubl conjugation systems. UbcH7/M4 shares 55 and
50% amino acid sequence identity with UbcH8 and UbcM8,
respectively. Furthermore, these E2s interact with the same E3
ligases, such as E6AP, HHARI, Parkin, and Dorfin (15, 24, 35,
36), to mediate protein ubiquitylation. However, UbcH7/M4 is
not functional in an ISGylation system (Fig. 5). Thus, it is
unlikely that general homology is closely related to functional
specificity among ubl systems. It has been suggested that dif-
ferences in surface charge distribution are critical for the dis-
crimination between ubiquitin and SUMO conjugation systems
(19). To date, we do not have any structural information for
ISG15 and Ubc8. It will be interesting to see if a specific
domain of ISG15 is responsible mainly for interacting with
UBE1L and Ubc8 and to see which major structural factors are
able to distinguish ISG15 from other ubls. In the ubiquitin
system, the interaction between E2 enzymes and target pro-
teins should be mediated by E3 enzymes (19). Thus, without
E3 enzymes, ubiquitylation could not occur. On the other
hand, Ubc9 can directly interact with target proteins and con-
jugate SUMO on the consensus sequence, which enables con-
jugation reactions without E3, although the efficiency of
SUMOylation increases dramatically in the presence of E3.
Ubc8 can mediate protein ISGylation without coexpression of
E3 enzymes in our transfection assays. From this perspective,
ISGylation seems to be closer to SUMOylation than ubiquity-
lation. However, it is still possible that E3 enzymes already
exist in the cell and that they enhance protein ISGylation upon
transfection with UBE1L and Ubc8.
UbcH8 was identified in a yeast two-hybrid screening
through its interaction with E6AP and was suggested to be an
ubiquitin E2 acting in conjunction with E6AP (24) and also
with other E3 proteins, such as Parkin, Dorfin, Staring, Efp,
and RLIM, based mainly on in vitro interaction between Ubc8
and E3s (2, 15, 23, 36, 51, 58). In our experiment, the reduction
of UbcH8 expression by shRNA was directly linked to down-
regulation of ISGylation upon IFN treatment in HeLa cells,
indicating that Ubc8 is responsible for protein ISGylation in
vivo (Fig. 6). Although we did not detect any change in protein
ubiquitylation in the same experiment, this result does not
prove that Ubc8 is not involved in ubiquitylation since it is
difficult to see changes in general ubiquitylation by reducing
the expression of a single E2. It is still possible that Ubc8 works
for both the ubiquitin system and the ISGylation system, de-
pending on the availability of other components. Ubiquitin and
other ubl systems are closely related to each other in their
functions. Nedd8 regulates the function of ubiquitin by modi-
fying cullin family proteins that are molecular scaffolds respon-
sible for assembling the ROC1/Rbx1 RING-based E3 ubiquitin
ligases (39). SUMO also modulates the ubiquitylation of cer-
tain proteins, such as PCNA and I	B, by competing for iden-
tical lysine residues (33). Thus, it will be interesting to analyze
whether there are possible interplays between the ISGylation
and ubiquitin pathways.
While we were preparing the present report, Zhao et al.
FIG. 7. Detection of ISG15 conjugation to specific target proteins. Plasmid constructs for ISG15 targets (pCAGGS-PLC1, pFlagCMV2-serpin
2A, pCEP-HA-Erk1, or pFlagCMV2-AML1B) were transfected to 293T cells in the presence or absence of a protein ISGylation system
(6His-mISG15, HA-hUBE1L, and Flag-UbcM8). Cells were harvested 48 h after transfection and analyzed either by direct Western blotting (A) or
by reciprocal pull-down assay followed by Western blotting (B, C, D, and E). Plasmids are identified by the ending letters and numbers of each
designation. Conj., conjugate; IgG, immunoglobulin G; WB, Western blot; PD, pull-down assay; IP; immunoprecipitation.
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came to a similar conclusion by identifying UbcH8 as a thio-
ester forming E2 with ISG15; they showed, using an in vitro
conjugation system, a dual functionality of UbcH8 towards
both ubiquitin and ISG15 (59). They also found, using an
siRNA approach, that UbcH8 is a major ISG15 E2 for IFN-
induced protein ISGylation. Our report confirms this finding
and provides additional characterizations to demonstrate that
Ubc8 functions as an ISG15 E2. In the present paper, we
showed (i) the direct interaction between ISG15 and Ubc8
with a yeast two-hybrid assay, (ii) the enzymatic function of
Ubc8 as an ISG15 E2 together with UBE1L with a transfec-
tion-based in vivo assay, and (iii) the importance of Ubc8 in
IFN-induced ISGylation with siRNA technology. In particular,
using a combination of siRNA and 2D Western blotting, we
were able to show that the decreased expression of UbcH8
protein caused a reduction of general protein ISGylation for
all of the targets. Furthermore, it is important to emphasize
that UbcM8 expression in vivo is dependent on the IFN-sig-
naling pathway. Together with data showing that Ubc8 is ca-
pable of directing ISGylation, the spatial-temporal availability
of this enzyme in vivo strongly argues that Ubc8 is a predom-
inant E2 for IFN-induced ISG15 conjugation to target pro-
teins. More importantly, we set up an in vivo assay system to
detect ISG15 target proteins based on the transfection of
ISG15, UBE1L, and Ubc8. In our system, we can detect pro-
tein ISGylation of specific proteins without knowing the
matching E3 enzyme, which was indispensable information for
use of the in vitro assay system (59). The novel protein ISGy-
lation assay system presented in this report provides a useful
and effective method for the identification and characteriza-
tion of ISG15 target proteins, which are critical for under-
standing the biological function of the protein ISGylation sys-
tem.
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